[8-K] Zentalis Pharmaceuticals, Inc. Reports Material Event

Rhea-AI Filing Summary

Zentalis Pharmaceuticals (ZNTL) furnished an update via Form 8-K. The company announced its financial results for the quarter ended September 30, 2025, and provided business updates. A press release was furnished as Exhibit 99.1 and a corporate presentation as Exhibit 99.2, both beginning November 10, 2025. The materials under Items 2.02 and 7.01 are furnished, not filed, and are not subject to Section 18 liabilities or automatically incorporated by reference.

0001725160FALSE00017251602025-11-102025-11-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

——————————————

FORM 8-K

——————————————

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 10, 2025

——————————————  

ZENTALIS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)   

——————————————

Delaware

001-39263

82-3607803

(State or other jurisdiction of incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

10275 Science Center Drive, Suite 200

San Diego, California 92121

(Address of principal executive offices) (Zip Code)

(858) 263-4333

(Registrant’s telephone number, include area code)

N/A

(Former name or former address, if changed since last report)  

——————————————

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, $0.001 par value per share			ZNTL			The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 10, 2025, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2025, and commented on certain business updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

Beginning November 10, 2025, spokespersons of the Company plan to present the information in the Corporate Presentation furnished as Exhibit 99.2 to this Current Report and incorporated herein by reference at conferences and in meetings with investors and analysts.

The information in Items 2.02 and 7.01 of this Current Report (including Exhibits 99.1 and 99.2 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

Exhibit No.						Description
99.1						Press Release issued on November 10, 2025
99.2						Corporate Presentation dated November 2025
104						Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZENTALIS PHARMACEUTICALS, INC.

Date: November 10, 2025

By:

/s/ Julie Eastland

Julie Eastland

President and Chief Executive Officer

FAQ

What did ZNTL disclose in this 8-K?

The company announced financial results for the quarter ended September 30, 2025, and furnished a press release (Exhibit 99.1) and corporate presentation (Exhibit 99.2).

Are the exhibits considered filed or furnished?

Items 2.02 and 7.01, including Exhibits 99.1 and 99.2, are furnished and not filed, and are not subject to Section 18 of the Exchange Act.

What is the date of the earliest event reported for ZNTL?

November 10, 2025.

Where is Zentalis Pharmaceuticals’ stock listed and under what symbol?

On The Nasdaq Global Market under the symbol ZNTL.

What exhibits accompany the 8-K?

Exhibit 99.1: Press Release issued on November 10, 2025; Exhibit 99.2: Corporate Presentation dated November 2025; Exhibit 104: Cover Page Interactive Data File.

What period do the announced results cover for ZNTL?

The quarter ended September 30, 2025.